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Abstract
Accumulation of the β-amyloid peptide (Aβ) is generally believed to be central to the induction of Alzheimer's disease, but the relevant
mechanism(s) of toxicity are still unclear. Aβ is also deposited intramuscularly in Inclusion Body Myositis, a severe human myopathy. The
intensely studied nematode worm Caenorhabditis elegans can be transgenically engineered to express human Aβ. Depending on the tissue or
timing of Aβ expression, transgenic worms can have readily measurable phenotypes that serve as a read-out of Aβ toxicity. For example,
transgenic worms with pan-neuronal Aβ expression have defects is associative learning (Dosanjh et al. 2009), while transgenic worms with
constitutive muscle-specific expression show a progressive, age-dependent paralysis phenotype (Link, 1995; Cohen et al. 2006). One particularly
useful C. elegans model employs a temperature-sensitive mutation in the mRNA surveillance system to engineer temperature-inducible muscle
expression of an Aβ transgene, resulting in a reproducible paralysis phenotype upon temperature upshift (Link et al. 2003). Treatments that
counter Aβ toxicity in this model [e.g., expression of a protective transgene (Hassan et al. 2009) or exposure to Ginkgo biloba extracts (Wu et al.
2006)] reproducibly alter the rate of paralysis induced by temperature upshift of these transgenic worms. Here we describe our protocol for
measuring the rate of paralysis in this transgenic C. elegans model, with particular attention to experimental variables that can influence this
measurement.
Protocol
1) Preparing Nematode Growth Media plates for paralysis assay.
Paralysis assays are performed on the standard Nematode Growth Media (NGM) plates routinely used for C. elegans propagation and genetics
(Stiernagle, 2006).
Relevant variables
The age of plates has a significant affect on the paralysis assay, as older plates tend to dry out. Use plates poured within one week of paralysis
assay. For ideal results, pour plates 3-4 days before initiation of synchronous worm populations [see (2) below]. For any experiment, only use
plates poured from the same batch.
Altering the size of the lawn (i.e. spotted vs. spread) and/or the type of bacteria will also alter the behavior of the worms. Paralysis assays can be
performed using alternative E. coli strains as a food source (e.g., the HT115 strain used in feeding RNAi experiments), but this can change the
kinetics of paralysis, thus requiring appropriate internal controls.
2) Preparation of Age-synchronous Worm Populations
Strain CL4176 (smg-1(cc546ts) I; dvIs27 [myo-3/ Aβ minigene + rol-6(su1006) marker gene] X is most commonly used for assaying Aβ-induced
paralysis. This strain and other transgenic models are available to academic researchers for a nominal fee from the Caenorhabditis Genetics
Center (http://www.cbs.umn.edu/CGC/).
Relevant variables
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1. Autoclave the NGM solution containing NaCl, Agar and Peptone in an Erlenmeyer flask and add the appropriate amounts of sterile CaCl2,
Uracil, Cholesterol, 1M MgSO4 and 1M KPO4. Aliquot 10 mL of liquid NGM into each 60 mm x 15 mm Petri Dish. Allow NGM to solidify
overnight at room temperature.
2. If testing for the effects of compounds/extracts, aliquot the extract onto each plate and use a spreader to evenly distribute the extract over the
surface of the plate. Allow extract to dry overnight at room temperature. Volumes over 1 mL will require more time to dry.
3. Spot each plate with 250 μL of E. coli strain OP5O grown in LB Media overnight for an optical density of 0.4-0.6. Allow bacteria to dry
overnight at room temperature.
1. To maximize the age synchrony of the test population it is preferable to start with a synchronized parental generation. A week before the
initiating the paralysis assay of the test population, use a platinum worm picker to transfer 20-30 gravid adults onto several 10 cm NGM plates
spread with OP50 for a 2 hour egg lay at 16°C (the permissive temperature for CL4176). Remove the gravid adults and allow the progeny to
grow for 7 days, by which time they will be "second day" gravid adults.
2. (Day 1) The second day gravid adults are used to prepare the age-synchronous test populations. For each experimental condition the object
is to generate triplicate plates containing 50-75 age-synchronous worms. Using a platinum worm picker, transfer 10-12 of the day 2 gravid
adults onto 60 mm (10 mL volume) NGM plates spotted with OP50. Allow the worms to lay eggs at 16°C for 2 hours, then pick off the adults
and allow eggs to hatch and grow at 16°C. At this point it is best to have someone who will not be scoring the plates to code them, so the
scorer will be blind to experimental conditions.The stage of embryonic development when eggs are laid (~ the 26-cell stage for wild type worms under optimal conditions) is a function of adult
age and nutrition. If the gravid adults used for preparation of the test population are older or starved, later stage eggs will be laid, reducing the
age synchrony of the population and the reproducibility of paralysis kinetics. It is essential than mono-axenic (i.e., only OP50 bacteria) cultures
are used (microbial contaminants can severely affect this assay), and reproducibility is highest if the triplicate plates have similar numbers of
worms.
3) Transgene Induction and Paralysis Assay
Relevant variables
The upshift of transgenic myo-3/Aβ worms must occur before they reach the mid L4 stage for paralysis to be initiated, as the myo-3 promoter is
developmentally regulated, and has significantly reduced expression in late L4 or adult worms. Similarly, expression of this transgene is blocked if
worms become starved, so it is essential that the worms are well-fed throughout the experiment. We have never observed a paralyzed worm to
recover under any conditions, and after 12-16 hr of upshift, all CL4176 worms will paralyze, even if they are downshifted to 16°C. In strain
CL4176, sufficient upregulation of transgene expression to cause paralysis can occur at lower temperatures (i.e., 20-25°C) although the timing of
paralysis will be altered. The paralysis rate depends on the specific transgenic strain used (we have constructed myo-3/Aβ strains with both faster
and slower rates than CL4176), so with alternative strains the scoring window may need to be adjusted.
4) Representative Results
Shown in Figure 1 is a plot of a paralysis curve for CL4176, both untreated and exposed to 6.27 mM caffeine (final concentration in NGM plate).
This treatment results in a highly statistically significant delay in paralysis of approximately 4 hrs, which we interpret as indicative of suppression
of Aβ toxicity in this model. Shown in Figure 2 is an independent experiment assaying the effects of cafestol, another compound found in coffee.
This plot is typical for treatments that do not impact Aβ toxicity. Note that in both experiments about half the untreated CL4176 populations are
paralyzed at 24 hr, and paralysis is complete by 28 hr. These are typical timeframes for paralysis of control CL4176 populations. Significant
deviations from this timing are indicative of altered environmental conditions or spontaneous deletion of transgene copies. (CL4176 contains a
chromosomally-integrated transgenic array with multiple copies of the myo-3/Aβ transgene. Although this transgenic array is normally quite
stable, any propagation of the strain at temperatures >16°C will select for rare worms that have undergone a spontaneous deletion of transgenes,
resulting in variants that will have reduced Aβ expression and slower paralysis results.)
Figure 1. Paralysis curve for strain CL4176 worms untreated or exposed to 6.27 mM caffeine (Sigma). The indicated times are from
initiation of temperature upshift. Error bars = S.E.M.
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1. (Day 3) Upshift plates to 25°C 48 hours after the end of the synchronous egg lay; worms should be at the third larval stage (L3). Plates
should be arranged without stacking in a 25°C incubator to allow all plates to reach 25°C at the same time.
2. (Day 4) Begin scoring the paralysis of worms (strain CL4176) at 18-20 hrs after the initiation of upshift. At this point, all worms in the
population should have reached the fourth larval (L4) stage. Continue scoring in two-hour increments until all worms on each of the plates are
paralyzed. For unknown reasons, paralysis is not even across the body length: the head region is the last part of the worm to cease moving.
Thus, worms that have recently initiated paralysis cannot translate across the plate, but can move their heads, thereby clearing bacteria
around their anterior and leaving a "halo" of cleared bacteria. These worms will invariably become completely paralyzed, and therefore worms
with halos are categorized as paralyzed. Some worms will not have halos but will also not show spontaneous movement; these are tested by
prodding with the worm picker. If a prodded worm cannot undergo a full body wave propagation upon prodding, it is also scored as paralyzed.
For efficient scoring, it is easiest to move the paralyzed worms to an unspotted sector of the plate so that they will not be unintentionally
rescored the next scoring period. (This also allows mis-categorized worms to demonstrate movement, allowing a scoring correction).
3. To generate a paralysis curve, at each time point the fraction of worms on each plate that have not been paralyzed is converted to a
percentage, and the average "unparalyzed" percentage is plotted against time from upshift initiation. (The rationale for plotting in this manner
is that the resulting curve is formally analogous to a survival curve, and thus can be analyzed using standard non-parametric survival
statistics.)Figure 2. Paralysis curve for CL4176 worms exposed to 0.48 mM cafestol (Sigma). Error bars = S.E.M.
Discussion
The protocol we have described can be effectively used to assay the effects of compounds on Aβ toxicity. Published examples include the effects
of Ginkgo biloba extract constituents (Wu et al. 2006) and reserpine (Arya et al. 2009). Compounds that have been protective against Aβ toxicity
in other systems have also been shown to be protective in this model (e.g., memantine, our unpublished results). An important rationale for
establishing this model is that the well-developed genetic and molecular tools available in C. elegans can be used to investigate mechanisms of
Aβ toxicity. Thus, the effects specific mutations on Aβ toxicity can be assayed (e.g., the effect of reducing insulin-like signaling by introducing a
daf-2 loss-of-function mutation, Florez-McClure et al. 2007), and this model can also be used to examine the effects of over-expression
transgenes (Fonte et al. 2008). We have recently made extensive use of this model to examine the effects on toxicity of single amino acid
substitutions in Aβ (unpublished data).
The transgenic model described here assays the effect of acute Aβ expression on muscle cell function. At the time of paralysis muscle cells and
their sarcomere are intact; the paralysis phenotype is not the result of muscle cell death. However, after paralysis ( ~48 hr after initial upshift)
there is a breakdown of muscle integrity and eventual death of the worms. We have not investigated this downstream effect of Aβ expression or
used it as a toxicity marker.
The inducible Aβ expression model described here is not appropriate for investigating treatments that modulate β-amyloid formation per se.
Although transgenic worms with constitutive Aβ expression form readily detectable amyloid deposits (Fay et al. 1998; Link et al. 2001), transgenic
worms with inducible Aβ expression rarely have amyloid deposits and the paralysis phenotype appears independent of amyloid deposition (Drake
et al. 2003). Our results are consistent with the view that acute toxicity of induced Aβ expression results from the accumulation of soluble
oligomeric Aβ, not amyloid deposition.
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